Attached files

file filename
EX-2.3 - EXHIBIT 2.3 - KEMET CORPfy2017_q4xex2x3xpjvoltamen.htm
EX-2.2 - EXHIBIT 2.2 - KEMET CORPfy2017_q4xex2x2xpjvoltamen.htm
EX-2.1 - EXHIBIT 2.1 - KEMET CORPfy2017_q4xex2x1xvoltmaster.htm
8-K - 8-K - KEMET CORPfy2017_q4xform8kxntsaleofe.htm


Exhibit 99.2
 
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 
The following unaudited pro forma condensed consolidated financial statements of KEMET Corporation ("KEMET" or the "Company") have been derived by applying pro forma adjustments to the historical consolidated financial statements of KEMET. The following unaudited pro forma condensed consolidated financial statements give effect to the sale by NEC TOKIN Corporation ("NEC TOKIN"), a joint venture between KEMET Electronics Corporation (a wholly-owned subsidiary of the Company) and NEC Corporation, of its electro-mechanical devices ("EMD") business, as if the sale occurred on April 1, 2015 for the unaudited pro forma condensed consolidated statements of operations (for the fiscal year ended March 31, 2016 and the nine-month period ended December 31, 2016) and as if the sale occurred on December 31, 2016 for the unaudited pro forma condensed consolidated balance sheet (as of December 31, 2016).
 
KEMET's investment in NEC TOKIN Investment is accounted for as an equity method investment under the provisions of Accounting Standards Codification (“ASC”) 323, “Investments — Equity Method and Joint Ventures,” (“ASC 323”). Under the equity method, an investor shall recognize its share of the earnings or losses of an investee in the periods for which they are reported by the investee in its financial statements rather than in the period in which an investee declares a dividend. An investor shall adjust the carrying amount of an investment for its share of the earnings or losses of the investee after the date of investment and shall report the recognized earnings or losses in income. An investor’s share of the earnings or losses of an investee shall be based on the shares of common stock and in-substance common stock held by that investor.
 
The unaudited pro forma condensed consolidated financial statements reflect the application of preliminary pro forma adjustments based upon available information and certain assumptions, described in the accompanying notes thereto, that management believes are reasonable under the circumstances. Actual results may differ materially from the assumptions within the accompanying unaudited pro forma condensed consolidated financial statements. The unaudited pro forma condensed consolidated financial statements have been prepared by management and are not necessarily indicative of the financial position or results of operations that would have been realized had the transaction occurred as of the dates indicated, nor is it meant to be indicative of any anticipated financial position or future results of operations that KEMET will experience going forward.
 
The following unaudited pro forma condensed consolidated balance sheet as of December 31, 2016 and unaudited pro forma condensed consolidated statement of operations for the nine-month period ended December 31, 2016, are based upon, derived from, and should be read in conjunction with the historical unaudited financial statements of KEMET included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on February 2, 2017. The following unaudited pro forma condensed consolidated statement of operations for the fiscal year ended March 31, 2016 is based upon, derived from and should be read in conjunction with the historical audited financial statements of KEMET included in its Annual Report on Form 10-K filed with the SEC on May 25, 2016.
 
The following pro forma adjustments include amounts translated from Japanese Yen to U.S. dollars, using the following exchange rates:

 
Japanese Yen to U.S. Dollar
December 31, 2016
117.4900

Nine-month period ended December 31, 2016
106.6296

Fiscal year ended March 31, 2016
120.7693







KEMET CORPORATION AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
as of December 31, 2016
(Amounts in thousands, except per share data)
(Unaudited)

 
KEMET Historical (a)
 
Gain on Sale of EMD
 
Elimination of EMD AOCI and Memo Accounts
 
Adjusted
ASSETS
 

 
 

 
 

 
 
Current assets:
 

 
 

 
 

 
 
Cash and cash equivalents
$
87,356








$
87,356

Accounts receivable, net
82,519








82,519

Inventories, net
154,519








154,519

Prepaid expenses and other
24,035








24,035

Total current assets
348,429

 

 

 
348,429

Property, plant and equipment, net of accumulated depreciation of $817,605 as of December 31, 2016
211,927








211,927

Goodwill
40,294







40,294

Intangible assets, net
30,204







30,204

Investment in NEC TOKIN
21,202


117,065

a
(9,957
)
b
128,310

Deferred income taxes
7,768







7,768

Other assets
2,712







2,712

Total assets
$
662,536

 
$
117,065

 
$
(9,957
)
 
$
769,644

LIABILITIES AND STOCKHOLDERS’ EQUITY
 

 
 

 
 

 
 
Current liabilities:
 

 
 

 
 

 
 
Current portion of long-term debt
$





$


$

Accounts payable
62,347







62,347

Accrued expenses
46,418







46,418

Income taxes payable
1,068







1,068

Total current liabilities
109,833

 

 

 
109,833

Long-term debt, less current portion
386,226







386,226

Other non-current obligations
72,704







72,704

Deferred income taxes
3,326







3,326

Stockholders’ equity:
 
 
 
 
 
 
 
Preferred stock, par value $0.01, authorized 10,000 shares, none issued








Common stock, par value $0.01, authorized 175,000 shares, issued 46,508 shares at December 31, 2016
465







465

Additional paid-in capital
445,950







445,950

Retained deficit
(304,565
)

117,065

a
(8,461
)
b
(195,961
)
Accumulated other comprehensive income
(51,024
)




(1,496
)
b
(52,520
)
Treasury stock, at cost (67 shares at December 31, 2016)
(379
)






(379
)
Total stockholders’ equity
90,447

 
117,065

 
(9,957
)
 
197,555

Total liabilities and stockholders’ equity
$
662,536

 
$
117,065

 
$
(9,957
)
 
$
769,644


See accompanying notes to Unaudited Pro Forma Condensed Consolidated Financial Statements






NOTES TO PRO FORMA BALANCE SHEET


a.
KEMET's proportionate share of NEC TOKIN's gain on the sale of the EMD business is calculated as follows:
 
Oku-Yen
$USD (in thousands)*
Sales price
¥
482.0

$
410,214

Less:
 
 
Carrying amount of EMD net assets
62.3

53,051

Remove AOCI
5.2

4,400

Transaction related fees and taxes
9.9

8,453

Gain on sale
404.5

344,308

KEMET's equity interest
34
%
34
%
KEMET's gain on sale (1)
¥
137.5

$
117,065

*Utilizing an exchange rate as of December 31, 2016 of 117.49 Japanese Yen to U.S. Dollar.

The gain calculation above is based upon preliminary estimates of the sales price (prior to working capital adjustments as outlined in the master sale and purchase agreement), carrying amount of the EMD net assets, the tax impact of the transaction and transaction fees.

b.
Reflects the elimination of KEMET’s portion of the EMD business' AOCI balance and the memo accounts related to the EMD business, including the proportionate share (based on relative fair values) of goodwill and the technology intangible asset as well as the step-up basis of the EMD business’ property plant and equipment. The relative fair values used to allocate goodwill to the EMD business are based upon the Company's current estimate. Adjustments are made utilizing an exchange rate as of December 31, 2016 of 117.49 Japanese Yen to U.S. Dollar.







KEMET CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
for the Nine-Month Period Ended December 31, 2016
(Amounts in thousands, except per share data)
(Unaudited)

 
KEMET Historical
 
Elimination of Interest Expense & EMD Net Income
 
Adjusted
Net sales
$
560,272

 
 
 
$
560,272

Operating costs and expenses:
 
 
 
 
 
Cost of sales
423,999

 
 
 
423,999

Selling, general and administrative expenses
78,551

 
 
 
78,551

Research and development
21,107

 
 
 
21,107

Restructuring charges
4,317

 
 
 
4,317

Write down of long-lived assets
6,193

 
 
 
6,193

Net (gain) loss on sales and disposals of assets
307

 
 
 
307

Total operating costs and expenses
534,474

 
 
 
534,474

Operating income (loss)
25,798

 
 
 
25,798

Non-operating (income) expense:
 

 
 
 
 

Interest income
(14
)
 
 
 
(14
)
Interest expense
29,751

 
 
 
29,751

Change in value of NEC TOKIN option
3,500

 
 
 
3,500

Other (income) expense, net
(6,683
)
 
 
 
(6,683
)
Income (loss) before income taxes and equity income (loss) from NEC TOKIN
(756
)
 
 
 
(756
)
Income tax expense (benefit)
4,440

 
 
 
4,440

Income (loss) before equity income (loss) from NEC TOKIN
(5,196
)
 
 
 
(5,196
)
Equity income (loss) from NEC TOKIN
271

 
(3,753
)
a
(3,482
)
Net income (loss)
$
(4,925
)
 
$
(3,753
)
 
$
(8,678
)
 
 
 
 
 
 
Net income (loss) per basic share
$
(0.11
)
 
 
 
$
(0.19
)
 
 
 
 
 
 
Net income (loss) per diluted share
$
(0.11
)
 
 
 
$
(0.19
)
 
 
 
 
 
 
Weighted-average shares outstanding:
 

 
 
 
 

Basic
46,469

 
 
 
46,469

Diluted
46,469

 
 
 
46,469


See accompanying notes to the Unaudited Pro Forma Condensed Consolidated Financial Statements





NOTES TO PRO FORMA Income Statement for the Nine-Month Period Ended December 31, 2016

a.
Elimination of the following: KEMET's portion of NEC TOKIN's interest expense, as the proceeds from the sale of EMD business were utilized to pay off all of NEC TOKIN's long term debt, KEMET's portion of the EMD business' net income and the depreciation of KEMET's memo accounts related to the EMD business (including technology and property plant and equipment basis step-up). Adjustments are made utilizing an exchange rate for the nine-month period ended December 31, 2016 of 106.6296 Japanese Yen to U.S. Dollar.






KEMET CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
for the Year Ended March 31, 2016
(Amounts in thousands, except per share data)
(Unaudited)
 
KEMET Historical
 
Elimination of EMD Memo Accounts, Interest Expense & EMD Net Income
 
Adjusted
Net sales
$
734,823

 
 
 
$
734,823

Operating costs and expenses:
 
 
 
 
 
Cost of sales
571,543

 

 
571,543

Selling, general and administrative expenses
101,446

 
 
 
101,446

Research and development
24,955

 
 
 
24,955

Restructuring charges
4,178

 
 
 
4,178

Write down of long-lived assets

 
 
 

Net (gain) loss on sales and disposals of assets
375

 
 
 
375

Total operating costs and expenses
702,497

 

 
702,497

Operating income (loss)
32,326

 

 
32,326

Non-operating (income) expense:
 

 
 

 
 

Interest income
(14
)
 
 
 
(14
)
Interest expense
39,605

 
 
 
39,605

Change in value of NEC TOKIN option
26,300

 
 
 
26,300

Other (income) expense, net
(2,348
)
 

 
(2,348
)
Income (loss) before income taxes and equity income (loss) from NEC TOKIN
(31,217
)
 

 
(31,217
)
Income tax expense (benefit)
6,006

 
 
 
6,006

Income (loss) before equity income (loss) from NEC TOKIN
(37,223
)
 

 
(37,223
)
Equity income (loss) from NEC TOKIN
(16,406
)
 
(2,955
)
a
(19,361
)
Net income (loss)
$
(53,629
)
 
$
(2,955
)
 
$
(56,584
)
 
 
 
 
 
 
Net income (loss) per basic share
$
(1.17
)
 
 
 
$
(1.23
)
 
 
 
 
 
 
Net income (loss) per diluted share
$
(1.17
)
 
 
 
$
(1.23
)
 
 
 
 
 
 
Weighted-average shares outstanding:
 

 
 
 
 

Basic
46,004

 
 
 
46,004

Diluted
46,004

 
 
 
46,004


See accompanying notes to the Unaudited Pro Forma Condensed Consolidated Financial Statements










NOTES TO PRO FORMA Income Statement for the Year-Ended March 31, 2016

a.
Elimination of the following: KEMET's portion of NEC TOKIN's interest expense, as the proceeds from the sale of EMD business were utilized to pay off all of NEC TOKIN's long term debt, KEMET's portion of the EMD business' net income and the depreciation of KEMET's memo accounts related to the EMD business (including technology and property plant and equipment basis step-up). Adjustments are made utilizing an exchange rate for the fiscal year ended March 31, 2016 of 120.7693 Japanese Yen to U.S. Dollar.